A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome

By sjmartinez • February 7, 2024

Hammond TC, Purbhoo MA, Kadel S, Ritz J, Nikiforow S, Daley H, Shaw K, van Besien K, Gomez-Arteaga A, Stevens D, Ortuzar W, Michelet X, Smith R, Moskowitz D, Masakayan R, Yigit B, Boi S, Soh KT, Chamberland J, Song X, Qin Y, Mishchenko I, Kirby M, Nasonenko V, Buffa A, Buell JS, Chand D, van Dijk M, Stebbing J, Exley MA. A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome. Nat Commun. 2024 Feb 6;15(1):974. doi: 10.1038/s41467-024-44905-z. PMID: 38321023.

Tags: Publications, Pulmonary, Critical Care & Sleep Medicine

Feasibility of cognitive testing and ecological momentary assessments using smartphones in middle aged and older adults with insomnia

Ghadimi S, Ereso J, Kaula AJ, Taptiklis N, Cormack F, Alessi C, Martin JL, Dzierzewski JM, Naeim A, Kremen S, Te T, Fung CH. Feasibility[...]

Unflavored electronic cigarette exposure induces alterations in airway ciliary structure and function

Durra A, Cherry C, Luo C, Hou E, Frauenpreis A, Purkayastha A, Passamano I, Makanani S, Castillo K, Lund A, Choi W, Sen C, Chandran[...]

Heterogeneity in internal medicine chief residency selection processes and role preparation: an opportunity for improvement

Jones BLH, López L, Garg M. Heterogeneity in internal medicine chief residency selection processes and role preparation: an opportunity for improvement. BMC Med Educ. 2025[...]